Health
EMA says ‘no new evidence’ to support changes to HRT warnings
The European Medicines Agency (EMA) says it has seen no new evidence that points to a need to amend the current labelling of HRT medicines.
On Monday (10 November), the US Department of Health and Human Services (HHS), led by Robert Kennedy, announced that the US medicines regulator, the FDA, would initiate the removal of ‘black box’ warnings from hormone replacement therapies (HRT). Black box warnings are used to indicate that a medication may present serious risks...
To read the rest of this article, click here.
Share this article:
EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.
-
European Commission4 days agoCommission hosts first Water Resilience Forum to drive action on Europe’s growing water challenges
-
Azerbaijan3 days agoBuilding peace through connectivity: A strategic outlook on Azerbaijan–Armenia normalization process
-
Internet4 days agoCommission fines X €120 million under the Digital Services Act
-
EU financial framework3 days agoCommission launches major package to fully integrate EU financial markets
